

QIBA DCE-MRI Synthetic Data


9/29/2011



Daniel Barboriak, M.D.

Neuroradiology

Duke University Medical Center



Disclosures

- ▶ Imaging core lab support from Eisai Pharmaceuticals, ACRIN, NIBIB / RSNA QIBA
- ▶ Member of GE Medical Systems Neuro MRI advisory board
- ▶ Pulse sequence support from Siemens Healthcare
- ▶ Dynamic contrast enhanced MR is an off-label use of gadolinium-based contrast agents

Justification

- DCE-MRI seen as a complex operation
- “A Rube Goldberg machine, device, or apparatus is a deliberately over-engineered or overdone machine that performs a very simple task in a very complex fashion, usually including a chain reaction. The expression is named after American cartoonist and inventor Rube Goldberg (1883-1970). Over the years, the expression has expanded to mean any confusing or complicated system.”

Justification

- "It is recommended that a means should be explored for the major industry players to develop a process for evaluation of both acquisition and *analysis software* and make appropriate selections. "
- Dynamic Contrast-Enhanced MRI--Meeting Report, CIP, Rockville MD, 11/2000
- Lack of standardized software still seen as a barrier to understanding the meaning of the parameters extracted, whether in clinical trials or in individual subjects:
 K_{Duke}^{trans} vs. $K_{MD\ Anderson}^{trans}$

Justification

- In order for DCE-MRI to be validated for clinical use, needs clear demonstration of utility as could be obtained in multi-center clinical trial
- Need to validate an approach from patient to quantitative metric
- Variation in software performance may be due to differences in solution algorithms, initial estimates, number of iterations, etc.

Important questions for DCE MRI analysis

- Which software package(s) to use?
- Does it make a difference?

DRO project – primary goals and objectives

- Overall goal: aid DCE-MRI analysis standardization by developing digital reference objects (DROs) simulating MRI with known parameters to evaluate and compare analysis implementations
- Provide **image datasets** and **verification protocols** to ensure that particular analysis packages can be used to extract K^{trans} and IAUGC with sufficient accuracy to meet claims of QIBA profile.

Profile description

- http://qibawiki.rsna.org/index.php?title=DC E-MRI_subctte
- **Quantitative microvascular properties, specifically transfer constant (K^{trans}) and blood normalized initial area under the gadolinium concentration curve (IAUGC_{BN}), can be measured from DCE-MRI data obtained at 1.5T using low molecular weight extracellular gadolinium-based contrast agents within a 20% within-subject coefficient of variation for solid tumors at least 2 cm in diameter.**
- Profile specified for use with: **patients with malignancy**, for the following indicated biology: **primary or metastatic**, and to serve the following purpose: **therapeutic response**.

Other QIBA activities

- Phantom development
 - Accuracy of T_1 mapping
- Multi-center test-retest trial of DCE-MRI

Secondary benefits

- Aiding the process of software verification for software developers in the pre-release phase
- Supporting FDA approval of software packages
- Comparing the performance of software packages after release using identical input data.

Deliverables

1. Implementation of simple Tofts model DRO
See
<https://dblab.duhs.duke.edu/modules/QIBAcontent/index.php?id=1>
2. Verification of dcmriS4 package
(<http://www.dcmri.org>)
3. Implementation of multi-flip T_1 mapping DRO
4. Extension of simulation to develop more realistic DROs
5. Development of verification protocols and integration into profiling activities
6. Creation of open source archives

Team introduction

- James MacFall, Ph.D. Duke
- David Radoff, M.S.

Open science paradigm

- Open source data
 - XML and DICOM
- Open source software tools
 - JSim (<http://www.physiome.org/jsim/>)
 - dcmriS4 (<http://www.dcmri.org>)
 - ImageJ (<http://rsbweb.nih.gov/ij/>)
 - Dcm4che (<http://www.dcm4che.org/>)

Implementation of simple Tofts model DRO


- Need to simulate a particular protocol
- Described in QIBA documents here:
[http://qibawiki.rsna.org/index.php?title=
MR Acquisition Protocols](http://qibawiki.rsna.org/index.php?title=MR_Acquisition_Protocols)
- Has 5 flip angles: 3, 6, 9, 15, 24, 35 degrees
- TR 5 – 7 ms
- Dynamic images at 25 - 35 degrees
- 5.5 minutes of imaging
- Extract VIF from imaging data

Implementation of simple Tofts model DRO

- Start with a synthetic input function (whole-body multi-organ model with delay/dispersion)

Barboriak DP, MacFall JR, Viglianti BL, Dewhirst Dvm MW. Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. *J Magn Reson Imaging*. 2008 Jun;27(6):1388-98

- Implemented as a JSim model and available on-line



Implementation of simple Tofts model DR0

- Create CTCs for tissues with $K^{\text{trans}} = \{0.01, 0.02, 0.05, 0.1, 0.2, 0.35\}$ and $v_e = \{0.01, 0.02, 0.05, 0.1, 0.2, 0.5\}$ using JSim

ParSet Pages Back Next Run All_Runs

Domain t

t.min	0
t.max	330
t.ct	6601
t.delta	.05

Model Inputs

K	.1	theta_angle	25
Ve	.5	contrastR1	.0045
S0_tissue	5E4	TR	5
T1_tissue	1E3	HCT	.45
T1_blood	1440	Ce_init	0
S0_blood	5E4	Cb(t)	fgen 1

Model Outputs

theta	.43633231	expon_tissu...	.98758638
Ksec	.00166667	SI_blood(t)	2.0726388E3
Cp(t)	.53862611	SI_tissue(t)	2.4995636E3
Ce(t)	.66589452	CbmilliM(t)	.29624436
Ct(t)	.33294726	Cet(t)	-4.2422804E-4
expon_blood...	.98991349		


File View Zoom

XY plot update after run

Data ToftsKermode_2p CbmilliM Curve 1 show

X-Expr

Y Log Autoscale Min 0 Max 1



29Sep11. 04:43

Graph Text

Source Run Time Debug
Loops Sensitivity Optimizer Notes Images

line 1 terminated normally

File Edit **Compile**

```
// initial conditions
when(t=t.min) {

    Ce = 0;

}

// ODEs
CbmilliM = Cb*1000;
Cp = CbmiliM/(1-HCT);
Ce:t = Ksec * ((Cp - Ce) / Ve);
Ct = Ve * Ce;
expon_blood = exp(-1*TR*((contrastR1*CbmiliM)+(1/Tl_blood))
SI_blood = S0_blood*sin(theta)*(1-expon_blood)/(1-(cos(theta)
expon_tissue = exp(-1*TR*((contrastR1*Ct)+(1/Tl_tissue)));
SI_tissue = S0_tissue*sin(theta)*(1-expon_tissue)/(1-(cos(theta)

}

//
// This implements the two parameter Tofts Kermode model:
//
//
//
//
// Cp(t)
// Cp(t) ---->|          |----> Cp(t)
//
// K
```


File View Zoom

XY plot update after run

Data ToftsKermode_2p CbmiliM Curve 1 show

X-Expr

Y Log Autoscale Min 0 Max 1



29Sep11. 04:43
Graph Text


Source Run Time Debug
Loops Sensitivity Optimizer Notes Images


line 1 terminated normally

Implementation of simple Tofts model DRO


- Translate CTCs into SI vs. t curves
- For initial software testing, sample at unrealistically high rates (0.5 sec / image) and high equilibrium magnetization (50,000)
- 10 x 10 pixel tissue samples
- VIF strip
- XML, DICOM

Implementation of simple Tofts model DR0





VIF



K^{trans} 0.35,
 v_e 0.5

Implementation of simple Tofts model DRO

- Data now released
- See beta version at
[http://dblab.duhs.duke.edu/modules/QIBAc
ontent/index.php?id=1](http://dblab.duhs.duke.edu/modules/QIBAc
ontent/index.php?id=1)

Verification of dcemriS4 package

- Background: Brandon Witcher, Volker Schmid, www.dcemri.org
- Importance of open source packages
- A reference method (not “gold standard”)
- An “open box” to compare to “black box” software
- Shape our expectations

Implementation of multi-flip T_1 mapping DRO

- Utility for QIBA
- Data is in the planning stages
- Proposal: T_1 {50 to 2000ms}, S_0 {1000 - 50,000}
- Patch size

Extension of simulation to develop more realistic DROs

- Consider software verification process as a series of hurdles
- Planning stages
- Reduce S_0
- Reduce sampling times
- Temporal jitter
- Add noise
 - At some point, assumptions about VIF shape come into play
 - Bias and reproducibility both become important

Development of verification protocols and integration into profiling activities

- The concept of “seal of approval” or “QIBA stamp”
- Challenge: summarizing multidimensional bias and reproducibility data into a “stamp” vs. “no stamp” decision
- Need for grading of “unknowns?”
- Are there tools we could use to automate iterative processes? CLIs? DICOM WG 23?

Creation of open source archives

- An area of active discussion
- Need to have an archive not only of DICOM, but XML, software and scripts

Other uses of synthetic data

- Investigations of alternative schemes
- A check for software in development phase
- Utility for FDA?
- All analyses fail at extremes: results may define the limitations of a given DCE-MRI acquisition technique

Community engagement

- Figures of merit for performance – the Rawlsian experiment
- Details of simulation extensions
- Automation tools – the “verification framework”

Communication

- Data, models etc: Barboriak lab:
<https://dbllab.duhs.duke.edu/> Look for QIBA link on right
- QIBA DCE-MRI committee wiki:
http://qibawiki.rsna.org/index.php?title=DCE-MRI_subctte
- QIBA synthetic data initiative:
[http://qibawiki.rsna.org/index.php?title=Synthetic DCE-MRI Data](http://qibawiki.rsna.org/index.php?title=Synthetic_DCE-MRI_Data)
- Discussion, comments:
http://groups.google.com/group/qiba_dcemri_dro

In conclusion

- Your input will make the DROs more useful, thanks in advance for your interest and comments